SXTP

60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SXTP

1 2 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/30	20:59	GlobeNewswire Inc.	Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/05/20	20:59	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/05/16	02:45	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Announces First Quarter 2024 Results	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/05/08	20:59	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/05/02	20:59	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/04/03	20:58	GlobeNewswire Inc.	60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/03/14	20:59	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/02/21	06:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/02/20	21:59	GlobeNewswire Inc.	60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/02/08	21:59	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/02/03	05:33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/02/03	05:31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/02/01	02:00	PR Newswire (US)	WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/02/01	01:15	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/01/30	23:45	PR Newswire (US)	WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/01/30	23:00	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/01/30	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/01/23	07:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/01/22	21:59	GlobeNewswire Inc.	60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/01/17	04:56	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2024/01/16	21:59	GlobeNewswire Inc.	60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2023/12/26	21:59	GlobeNewswire Inc.	60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2023/11/15	21:29	GlobeNewswire Inc.	60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2023/10/19	21:31	GlobeNewswire Inc.	60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2023/10/13	05:16	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2023/09/19	05:16	GlobeNewswire Inc.	60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2023/09/06	20:31	GlobeNewswire Inc.	60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2023/08/30	20:32	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2023/08/22	20:31	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc
2023/08/15	20:31	GlobeNewswire Inc.	60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov	NASDAQ:SXTP	60 Degrees Pharmaceuticals Inc